TTM
−$71.28M
YoY change
-12.4%
5Y CAGR
—
Peak year (2021)
−$9.04M
Cumulative EBITDA
−$225.20M
EBITDA history chart for Alto Neuroscience (ANRO) from 2021 to 2025
Latest: −$60.11M
EBITDA growth chart for Alto Neuroscience (ANRO) from 2021 to 2025
Latest: -12.4%
EBITDA history table for Alto Neuroscience (ANRO) from 2021 to 2025
| 2025 | −$60.11M | -12.4% | +$8.50M | ||
| 2024 | −$68.61M | +98.5% | −$34.05M | ||
| 2023 | −$34.56M | +26.3% | −$7.19M | ||
| 2022 | −$27.37M | +202.7% | −$18.33M | ||
| 2021 | −$9.04M | — | — |
- 2025−$60.11M-12.4%
- 2024−$68.61M+98.5%
- 2023−$34.56M+26.3%
- 2022−$27.37M+202.7%
- 2021−$9.04M—
EBITDA values are taken from Alto Neuroscience's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About EBITDA at Alto Neuroscience (ANRO)
According to Alto Neuroscience's latest reported financial statements, the company's current EBITDA (TTM) is −$71.28M. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a common proxy for operating cash generation that strips out non-cash charges (depreciation and amortization) and capital structure effects (interest, taxes). Useful for comparing companies with different leverage and asset bases — see operating income and net income for fully GAAP figures.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
The 2025 reading of Alto Neuroscience (ANRO) EBITDA is −$60.11M – declined 12.4% year-over-year.
The highest annual EBITDA of −$9.04M was reported in 2021. The lowest in the available history was −$68.61M in 2024.
Alto Neuroscience EBITDA by Year
Alto Neuroscience EBITDA 2025: −$60.11M
In 2025, Alto Neuroscience reported EBITDA of −$60.11M, declined 12.4% below 2024.
Alto Neuroscience EBITDA 2024: −$68.61M
Alto Neuroscience EBITDA in 2024 was −$68.61M, surged 98.5% from 2023. This figure represents the lowest annual value in the available history.
Alto Neuroscience EBITDA 2023: −$34.56M
2023's EBITDA for Alto Neuroscience came in at −$34.56M, grew 26.3% from 2022.
Alto Neuroscience EBITDA 2022: −$27.37M
Alto Neuroscience posted EBITDA of −$27.37M in 2022, surged 202.7% from 2021.
Alto Neuroscience EBITDA 2021: −$9.04M
Alto Neuroscience EBITDA in 2021 was −$9.04M.
See more financial history for Alto Neuroscience (ANRO).
Sector peers by EBITDA
Healthcare peers of Alto Neuroscience (ANRO), ranked by their latest EBITDA
| $41.05B | |
| $28.26B | |
| $27.94B | |
| $24.43B | |
| $23.06B | |
| $19.83B | |
| $17.63B | |
| $16.90B |
- $41.05B
- $28.26B
- $27.94B
- $24.43B
- $23.06B
- $19.83B
- $17.63B
- $16.90B
Frequently asked questions
Alto Neuroscience (ANRO) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation